Education
About Us
Working with TipRanks
Follow Us
CareDx (CDNA)
NASDAQ:CDNA
CDNA Stock Chart & Stats
$15.01
$0.67(2.95%)
At close: 4:00 PM EST
$15.01
$0.67(2.95%)
Day’s Range― - ―
52-Week Range$10.96 - $25.95
Previous CloseN/A
Volume177.07K
Average Volume (3M)1.12M
Market Cap
$1.00B
Enterprise Value$614.76M
Total Cash (Recent Filing)$194.22M
Total Debt (Recent Filing)$27.64M
Price to Earnings (P/E)16.3
Beta1.20
Next Earnings
Mar 04, 2026EPS Estimate
<0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.03
Shares Outstanding51,432,640
10 Day Avg. Volume957,989
30 Day Avg. Volume1,123,784
Financial Highlights & Ratios
PEG Ratio-0.17
Price to Book (P/B)2.99
Price to Sales (P/S)3.39
P/FCF Ratio35.80
Enterprise Value/Market Cap0.61
Enterprise Value/Revenue1.72
Enterprise Value/Gross Profit2.55
Enterprise Value/Ebitda-35.80
Forecast
1Y Price Target
$22.00Price Target Upside46.57% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering4
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Financial PerformanceNet income was $1.7M, or $0.03 per share, beating our estimated loss of $4.2M.
Guidance And ExpectationsManagement has raised FY2025 revenue guidance to $372-376M, with adjusted EBITDA of $35-39M.
Revenue GrowthTotal revenue was $100.1M, representing 20.7% YoY growth and beating our projection of $95.3M.
Bears Say
Market UncertaintyThe draft LCD remains an overhang on the model, with clarity not expected until the first part of 2026, affecting the potential for an upgrade thesis.
Operational PerformanceRevenues and volumes excluding prior periods missed expectations due to softer-than-expected kidney transplant volumes and issues with prior-period collections.
Regulatory ChallengesThe draft LCD from MolDX is still an overhang, and it may be resolved in 1Q26.
CareDx News
CDNA FAQ
What was CareDx’s price range in the past 12 months?
CareDx lowest stock price was $10.96 and its highest was $25.95 in the past 12 months.
What is CareDx’s market cap?
CareDx’s market cap is $1.00B.
When is CareDx’s upcoming earnings report date?
CareDx’s upcoming earnings report date is Mar 04, 2026 which is in 71 days.
How were CareDx’s earnings last quarter?
CareDx released its earnings results on Nov 04, 2025. The company reported $0.03 earnings per share for the quarter, beating the consensus estimate of -$0.082 by $0.112.
Is CareDx overvalued?
According to Wall Street analysts CareDx’s price is currently Undervalued.
Does CareDx pay dividends?
CareDx does not currently pay dividends.
What is CareDx’s EPS estimate?
CareDx’s EPS estimate is <0.01.
How many shares outstanding does CareDx have?
CareDx has 51,432,640 shares outstanding.
What happened to CareDx’s price movement after its last earnings report?
CareDx reported an EPS of $0.03 in its last earnings report, beating expectations of -$0.082. Following the earnings report the stock price went up 13.843%.
Which hedge fund is a major shareholder of CareDx?
Currently, no hedge funds are holding shares in CDNA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
CareDx Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$22.00 (46.57% Upside)
$22.00 (46.57% Upside)
Blogger Sentiment
Neutral
CDNA Sentiment 50%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 417.4K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.4%
Last 30 Days ▲ 3.9%
Last 30 Days ▲ 3.9%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-23.91%
12-Months-Change
Fundamentals
Return on Equity
24.11%
Trailing 12-Months
Asset Growth
-9.37%
Trailing 12-Months
Company Description
CareDx
CareDx, Inc. is a leading molecular diagnostics company focused on the transplantation sector. The company specializes in developing and providing innovative solutions for transplant patient management, with a core emphasis on organ transplant diagnostics. CareDx's primary products include AlloSure, a non-invasive blood test that assesses kidney transplant rejection, and AlloMap, a heart transplant monitoring test. By delivering advanced genomic insights, CareDx aims to improve patient outcomes and enhance the quality of care in transplant medicine.
CDNA Company Deck
CDNA Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflected a strong quarter with significant revenue growth and operational improvements, including successful product launches and strategic initiatives. However, the overall market conditions for transplant volumes have been flat, and the expected impact from the IOTA program has not yet been realized.View all CDNA earnings summariesCDNA Stock 12 Month Forecast
Average Price Target
$22.00
▲(46.57% Upside)
Technical Analysis
Ownership Overview
Currently, No data available
---